Latest filing published 12 Feb 2024 for ImmunoGen, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Stacy Ann Coen in ImmunoGen, Inc., where the filings describe the role as senior executive. Over a trading history stretching from 30 June 2021 to 12 February 2024, the count stands at 26 filings.
Every open-market trade on record is a sale: 8 sales worth €4.4M. The rest of the record consists of 5 share grants and 12 option exercises. 2024 to date brings no purchases and 1 sale.
The record was last updated on 12 February 2024 with a transaction in ImmunoGen, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations